A link to a betting market on whether Lilly's retatrutide gets FDA approval, with no reporting or detail on the drug's actual status.
Recap by typeshit. Post by Polymarket on X.
BMO's Evan Seigerman expects US share losses to weigh on Ozempic sales, while the 25% CagriSema figure comes from a post-hoc subgroup, not the full trial's 22.7%.
Beauty companies are reportedly exploring products aimed at facial changes linked to rapid weight loss on GLP-1 drugs.
A search page for retatrutide news with no specific story attached, so there is little new beyond recent coverage.
2:06:48
A live Q&A stream from DOWNSIZED taking viewer questions about GLP-1 medications, including Zepbound, Wegovy and Foundayo.
The visits came in the country's largest healthcare system, with the trend credited to wellness influencers and young people among those affected.
The GLP-1 Bridge pilot runs through 2027 and covers approved pills and shots for eligible Part D and Advantage enrollees, with no deductible.
Loading…